ADME and Predictive Toxicology Keynote Speakers

Franck Atienzar Head/Associate Director, UCB Pharma SA Franck Atienzar obtained his PhD in Environmental Toxicology at the University of Plymouth(UK) in 2000. After a short experience at Sigma -Aldrich (technical Service: molecular biology specialist, France), he joined UCB-Pharma in 2002 as Head of the In Vitro Toxicology Unit. His objectives are to implement strategies and technologies (measure of gene expression, hepatotoxic, genotoxic and cytotoxic markers, detection of phospholipidosis, ....) in the context of early toxicological assessment of pharmaceutical compounds. Franck, who also works for the European commission as an independent expert, evaluates scientific projects submitted for European funding. So far, he has published part of his work in 4 book chapters and in 23 peer-reviewed journals.
Robert Guttendorf Senior Consultant, DMPK, Aclairo Pharmaceutical Development Group Robert J. Guttendorf, R.Ph, Ph.D. is a Senior Consultant, DMPK, at Aclairo Pharmaceutical Development Group, Inc. in Vienna, VA. Dr. Guttendorf provides scientific, regulatory, strategic planning, and due diligence advice and support for drug discovery and development. He has held leadership positions in small biotech and large pharmaceutical companies, including Director of Discovery and Preclinical Development at Pfizer Global R&D and Parke-Davis Pharmaceutical Research, Scientific Strategy Advisor at Pfizer, Vice President of Pharmacology and Biopharmaceutics at Advancis (Middlebrook) Pharmaceutical Co., and Vice President of Pharmacology and Experimental Therapeutics at Sequoia Pharmaceuticals. He has directed ADME/PK support for discovery through NDA across a variety of therapeutic areas, overseeing numerous nonclinical pharm-tox and clinical pharmacology programs, and a host of regulatory submissions. At Parke-Davis/Pfizer, he helped pioneer the implementation of higher throughput ADME/PK screening approaches in drug discovery and was instrumental in defining best practices for DMPK in drug discovery and development. In addition, he led Pfizer’s Global PDM organization in evaluating and implementing new strategies to enhance the quality and R&D survival of exploratory development candidates. He has presented and published numerous papers on various topics in ADME/PK, including the strategic use of ADME data to improve drug discovery and development. He received a B.S. in Pharmacy from West Virginia University and a Ph.D. in Pharmaceutical Sciences from the University of Kentucky.
Magnus Ingelman Sundberg Professor/Head, Karolinska Institutet Magnus Ingelman-Sundberg is a PhD and BSc.Med. He is Chairman of the Editorial Board of Pharmacogenetics and Genomics and Chairman of the Microsomes and Drug Oxidation organisation. He has been working with pharmacogenomics at EMA (PGWP) since 2005. He has 350 original papers, 17 500 citations and an h-factor of 72. He is ranked as the 4th most highly impact researcher in the field of drug metabolism (www.cytochrome.net ) and one of the worlds most cited authors within the category Pharmacology http://isihighlycited.com/ . The current research is centered about genetic predictors for drug response and adverse drug reactions.